Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)

Inclusion Criteria: * Histologically confirmed adenocarcinoma of pancreas metastatic to liver and/or lungs or peritoneal surface. (a.k.a. Stage IV B). * No prior chemotherapy with Gemzar, Xeloda and Taxotere. * Measurable disease: Any mass reproducibly measurable in two perpendicular diameters by x-ray, physical examination, CT or MRI scans. * The following lesions conventionally are not considered measurable: * CNS lesions * Blastic or lytic bone lesions (which should be documented and followed) * Radiated lesions unless progression after RT is documented * Ineligible for other high priority national or institutional studies * Prior radiation and surgery allowed: * \> 3 weeks since surgery * \> 4 weeks since RT * Non pregnant females who are not breast feeding with a negative serum or urine β-HCG test within 1 week of starting the study. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter. * Clinical Parameters: * Life expectancy \> 2 months * Age 18 - 70 years old * Performance status 0-2 (ECOG) * Peripheral Neuropathy must be \< grade 1 * Able to tolerate oral medications * Required initial laboratory data: * Absolute Neutrophil Count \> 1,500 μl * White Blood Count \> 3,000/μl * Platelet count \> 100,000/μl * BUN \< 1.5 x normal * Creatinine \< 1.5 normal * Hemoglobin \> 8.0 g/dl * Serum Albumin \> 3 mg/dl * Total Bilirubin \< 2.0 mg/dl * SGOT, SGPT, Alkaline Phosphatase SGOT and SGPT may be up to 3.0 x ULN if Alk Phos \< 2.0 x ULN; or Alk Phos may be up to 3.0 x ULN if SGOT and SGPT are \< 2.0 x ULN Exclusion Criteria: * Hypersensitivity: Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80 must be excluded. * Informed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts. * The patient has not had a prior malignancy in last 5 years other than curatively treated carcinoma in-situ of the cervix or non-melanoma skin cancer * No serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g., serious infection). * Patients with brain metastases are excluded. * Patients known to have HIV will be excluded.